Biotech News

iRhythm Announces Approval of $200 Million Share Repurchase Program

iRhythm (IRTC)iRhythmFDA / regulatory

iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that on November 10, 2026, its Board of Directors approved a share repurchase program with authorization to purchase up to $200 million of the company’s outstanding common stock.

Related news

IRTCiRhythm2026-11-17 21:35 EST

iRhythm Announces $100 Million Accelerated Share Repurchase Agreement

ICUSeaStar Medical2026-11-03 13:21 EST

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

IRTCiRhythm2026-11-06 14:15 EST

iRhythm Holdings to Participate in Upcoming Investor Conferences

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

ICUSeaStar Medical2026-10-07 12:16 EST

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

VTAKCatheter Precision2026-10-29 20:15 EST

Flyte Aviation Expands International Operations to Canada

JNJJohnson & Johnson2026-10-16 10:31 EST

CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma

ICCMIceCure Medical2026-10-20 11:55 EST

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

HYPRHyperfine2026-11-03 21:05 EST

Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences

iRhythm

Ambulatory Cardiac Monitoring iRhythm is a digital healthcare company focused on detecting and characterizing cardiac arrhythmias. It combines wearable biosensors, cloud-based analytics and proprietary algorithms to convert extended electrocardiographic recordings into clinically actionable reports. Zio Platform The Zio portfolio...

Recent company news

Stock data

Close
94.24 USD
Market cap
3.47B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States